Drug class

Beta-Blockers (Systemic)

Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body. Read more about Beta-Blockers (Systemic)

386 drugs in this class 143 manufacturers

Advertisement

Drugs in Beta-Blockers (Systemic)

Showing 64–72 of 386 drugs

SOTALOL HCL

ANTIARRHYTHMIC - CLASS III · LIFE-THREATENING VENTRICULAR TACHYCARDIA ·+2
ALTATHERA PHARM

ESMOLOL HCL

BETA-BLOCKERS (SYSTEMIC) · PERIOPERATIVE HYPERTENSION ·+3
EUGIA US LLC

PROPRANOLOL HCL

BETA-BLOCKERS (SYSTEMIC) · PHEOCHROMOCYTOMA ADJUNCT THERAPY ·+7
ROXANE/WEST-WAR

METOPROLOL TARTRATE

BETA-BLOCKERS (SYSTEMIC) · ACUTE MYOCARDIAL INFARCTION ·+1
APP/FRESENIUS K

ESMOLOL HCL

BETA-BLOCKERS (SYSTEMIC) · PERIOPERATIVE HYPERTENSION ·+3
APP/FRESENIUS K

CARVEDILOL

ALPHA-BETA BLOCKERS · HYPERTENSION ·+2
BAYSHORE PHARMA

BETAXOLOL HCL

BETA-BLOCKERS (SYSTEMIC) · HYPERTENSION
GSK Consumer Healthcare
Filter & compare in the drug finder → Opens the drug finder with Beta-Blockers (Systemic) preselected. Add indication or manufacturer filters there.

About Beta-Blockers (Systemic).

Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body.

By blocking cardiac beta-1 and peripheral beta-2 receptors, these medications exert negative inotropic and chronotropic effects, slowing the heart rate, decreasing myocardial contractility, and lowering systemic arterial blood pressure.

They are primarily indicated across cardiovascular medicine for the management of hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, and chronic heart failure with reduced ejection fraction.

Additionally, systemic beta-blockers play key therapeutic roles in non-cardiovascular conditions, including migraine prophylaxis, essential tremor, and the symptomatic management of thyrotoxicosis.